PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB) – Final assessment now available

This is the pharmaceutical Joint Assessment PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In August, 2020, the European Commission granted marketing authorisation for pretomanide (pretomanid FGK) in combination with bedaquiline and linezolid for the treatment […]

RCR01-RCR15 Covid-19 Rolling Collaborative Review – Second round of reviews now available

As part of its response to the Covid-19 pandemic, EUnetHTA is working to output ‘Rolling Collaborative Reviews (RCR)’. The objective of such reviews is to provide decision-makers with a timely synthesis of available evidence on the comparative effectiveness of therapeutic health technologies relevant to the management of the current pandemic. EUnetHTA is pleased to announce […]

OTCA26 Obesity Surgery Project – Project Plan now available

EUnetHTA is pleased to announce the project description and planning for 26th Other Technologies Collaborative Assessment “Surgical procedures for treatment of obesity” is now available for access. The relevance of the topic lies in evidence suggesting that bariatric surgery decreases the risk of premature death and other physical morbidities, but the effectiveness and safety of […]

Final Week – EUnetHTA Open Call for Early Dialogue Requests

The EUnetHTA ED Secretariat is holding an Open Call to fill the slots available for EDs through May 31, 2021. EUnetHTA will aim to conduct 1 ED per month with a maximum 8 EDs during the EUnetHTA prolongation period. The Open Call was opened on July 3, 2020 and will run through to August 15, […]